Influenza Vaccine Market By Type (Inactivated, Live Attenuated), By Valency (Quadrivalent, Trivalent), By Age Group (Pediatric, Adults), By Distribution Channel (Hospitals And Retail Pharmacies, Government Suppliers), And Region for 2024– 2031

Influenza Vaccine Market Valuation – 2024-2031

The strong government immunization programs, more accessibility to healthcare facilities worldwide, and growing awareness of the need for vaccination in preventing influenza epidemics are driving the global Influenza Vaccine Market. According to the analyst from Market Research, the Influenza Vaccine Market is estimated to reach a valuation of USD 10.73 Billion over the forecast period 2031, by subjugating around USD 6.44 Billion valued in 2023.

The growing awareness campaigns and government activities encouraging vaccination support the market for influenza vaccines. The continued need for effective preventative measures against seasonal influenza outbreaks enables the market to grow at a CAGR of 6.59% from 2024 to 2031.

Influenza Vaccine MarketDefinition/Overview

An influenza vaccine is a prophylactic drug that protects people from catching influenza, also known as the flu. It works by activating the immune system to create antibodies against certain strains of the influenza virus, lowering the risk of infection and related consequences. The vaccination often contains inactivated influenza viruses or viral components, allowing the immune system to recognize and defend against the virus without becoming ill.

Furthermore, the influenza vaccine’s principal application is to prevent seasonal influenza outbreaks by developing immunity against common strains of the virus. It is also advised for people who are more likely to develop severe influenza complications, such as the elderly, small children, pregnant women, and those with underlying health issues.

What are the Aspects Influencing the Growth of the Influenza Vaccine Market?

Rising public awareness of the health concerns connected with influenza and the benefits of vaccination has resulted in rising demand for influenza vaccines. Governments and international health organizations, such as the World Health Organization, promote flu vaccination, especially among vulnerable populations such as the elderly, children, and healthcare professionals.

The discovery of new and more effective vaccines has been a key driver for the market. Flu vaccines are becoming more appealing to both healthcare providers and patients due to innovations like quadrivalent vaccines, which protect against four different flu viruses, and cell-based manufacturing, which speeds up production and may be more effective than old egg-based methods.

Furthermore, many governments have introduced laws to help fund flu vaccination programs, making vaccines more available to a larger population. This assistance frequently involves subsidies, reimbursements, or even free vaccination programs, which boost immunization rates and fuel market expansion.

What are the Primary Challenges Faced by the Influenza Vaccine Market?

Each year, influenza vaccines are developed based on projections about the strains that are most likely to spread throughout the upcoming flu season. However, there is always the possibility that the circulating virus strains will not match the vaccination strains, drastically reducing the vaccine’s effectiveness. This mismatch between the vaccine and the circulating strains reduces public trust and immunization rates, ultimately limiting market growth.

The production of influenza vaccines is a complex and time-sensitive biological process, and any disruption will have an impact on supply. Also, delivering immunizations to all regions, especially rural and undeveloped ones, remains a logistical difficulty. These causes cause shortages or delays, limiting vaccine coverage and effectiveness.

Furthermore, despite the known benefits of influenza vaccination, vaccine hesitancy remains a substantial concern. Misinformation, fear of side effects, and skepticism of pharmaceutical corporations or government health advice all contribute to reduced vaccination rates, impeding the market demand.

Category-wise Acumens

What Factors Contribute to the Increasing Demand for Inactivated Influenza Vaccines?

According to analyst, the inactivated influenza vaccine segment is expected to dominate within the Influenza Vaccine Market. Inactivated influenza vaccines have long been known to provide significant flu protection. They are recommended for their potential to produce a significant immune response and known safety profile, especially for immunocompromised persons and older adults.

Continuous advancements in vaccine production technology, such as better antigenic match procedures and adjuvant formulations, improve the immunogenicity and efficacy of inactivated vaccines. These advances add to their broad use and market dominance.

Furthermore, Inactivated vaccines are widely recognized and utilized around the world because they are suitable for a wide range of demographic groups, including young children and the elderly. Healthcare providers and public health groups have strongly endorsed their usefulness in preventing severe influenza-related complications, which contributes to their high adoption rate.​

What Benefits Does the Quadrivalent Offer for the Influenza Vaccine Market?

The quadrivalent segment is estimated to hold the largest share of the Influenza Vaccine Market during the forecast period. Quadrivalent influenza vaccines are meant to protect against four strains of the influenza virus (two influenza A viruses and two influenza B viruses), providing greater protection than trivalent vaccines, which cover three strains. This expanded scope of protection appeals to public health strategies aimed at increasing vaccination coverage.

Leading health organizations, such as the Centers for Disease Control and Prevention (CDC), frequently encourage the use of quadrivalent vaccines, particularly for children, because they may provide superior protection against circulating flu viruses. These recommendations drive up the use and demand for quadrivalent vaccinations.

Furthermore, many national immunization programs have switched to quadrivalent vaccines to improve the efficacy of their flu preventive measures. This move is motivated by the potential to reduce the number of flu-related hospitalizations and fatalities, making quadrivalent vaccines increasingly attractive in public health campaigns.

Gain Access to Influenza Vaccine Market Report Methodology

Country/Region-wise Acumens

What are the Drivers Contributing to the Dominance of North America in the Market?

North America is estimated to dominate the Influenza Vaccine Market during the forecast period. North America, particularly the United States and Canada, has a strong healthcare system that allows for extensive vaccine distribution and delivery. This modern infrastructure enables widespread immunization campaigns and assures high vaccine coverage throughout the population.

Strong government support for flu vaccination programs, including CDC recommendations and vaccine subsidies, is critical to high vaccine uptake. These restrictions are frequently combined with public health campaigns emphasizing the significance of influenza vaccination.

Furthermore, North America’s people are highly mindful of their health. Regular educational initiatives regarding the benefits of flu vaccination and the hazards associated with influenza help to increase vaccination rates. This awareness is further encouraged by healthcare practitioners’ proactive attitude to promoting flu vaccines to people of all ages.

What Factors Influence the Market of Influenza Vaccines in the Asia Pacific Region?

The Asia Pacific region is estimated to exhibit the highest growth during the forecast period. Many Asia-Pacific countries are establishing more comprehensive immunization programs, including influenza vaccines, with a focus on high-risk populations such as the elderly, children, and healthcare workers. Governments are also conducting public awareness campaigns and giving financial support or subsidies for vaccinations, which encourages increased uptake.

The Asia Pacific region is experiencing considerable growth in healthcare spending, driven by expanding economies such as China and India. This rise in the healthcare budget enables improved healthcare services and access to vaccines, especially influenza vaccines, which contributes to market growth.

Furthermore, the Asia-Pacific population is growing more aware of the value of preventive healthcare. Increased knowledge of the severity of influenza and the benefits of immunization is driving up demand for flu vaccines. This shift toward preventative treatments is also reinforced by the increasing middle class, which has more disposable resources to invest in health.

Competitive Landscape

The competitive landscape of the Influenza Vaccine Market is characterized by a varied range of businesses working to develop and deliver effective vaccinations to combat seasonal flu outbreaks. Also, market participants are always engaged in research and development operations to address evolving influenza virus strains and improve vaccine formulations, earning a competitive advantage.

Some of the prominent players operating in the Influenza Vaccine Market include

Pfizer, Sanofi, GlaxoSmithKline, Merck & Co., AstraZeneca, Johnson & Johnson, AbbVie, Hoffmann-La Roche Ltd., Eli Lilly and Company, Bharat Biotech International Limited, CSL Limited, Mylan N.V., Novartis International AG, Serum Institute of India Ltd., Walgreens Boots Alliance, McNeil Consumer Healthcare, Seqirus, Shinogi Co.

Latest Developments

• In May 2024, Novavax, a protein-based vaccine startup, signed a deal with Sanofi to co-develop and co-commercialize a combination vaccine against both COVID-19 and influenza.
• In May 2024, Cadila Pharmaceuticals, an Indian business, released a new influenza vaccine called Cadiflu Tetra. This vaccine targets four types of influenza viruses, providing broader protection against seasonal flu.

Report Scope

Influenza Vaccine Market, By Category

Type

• Inactivated
• Live Attenuated

Valency

• Quadrivalent
• Trivalent

Age Group

• Pediatric
• Adults

Distribution Channel

• Hospitals & Retail Pharmacies
• Government Suppliers
• Others

Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.